DUBLIN – Shares in both Sillajen Inc. and Transgene SA took a hit Friday on news that an independent data monitoring committee recommended that a phase III trial of the oncolytic virus pexastimogene devacirepvec (Pexa-Vec) in advanced liver cancer cease enrolling patients, following an interim futility analysis, which showed that the study was not going to meet its objectives.